U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H45N3O4S.CH4O3S
Molecular Weight 663.888
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NELFINAVIR MESYLATE

SMILES

CS(O)(=O)=O.[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC3=CC=CC=C3)NC(=O)C4=C(C)C(O)=CC=C4)[C@@H](C2)C(=O)NC(C)(C)C

InChI

InChIKey=NQHXCOAXSHGTIA-SKXNDZRYSA-N
InChI=1S/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1

HIDE SMILES / InChI

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C32H45N3O4S
Molecular Weight 567.782
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020778s035,020779s056,021503s017lbl.pdf

Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Nelfinavir is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir is marketed under the brand name Viracept.

CNS Activity

Curator's Comment: Nelfinavir has poor penetration into the macaque's brain and CSF, and P-gp inhibition at the BBB by zosuquidar enhanced the distribution of nelfinavir into the brain by 146-fold.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
12.0 nM [IC50]
100.0 µM [IC50]
7.3 µM [IC50]
5.1 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VIRACEPT

Approved Use

VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV infection.

Launch Date

8.5821122E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.7 mg/L
1250 mg 2 times / day steady-state, oral
dose: 1250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3 mg/L
750 mg 3 times / day multiple, oral
dose: 750 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4 mg/L
1250 mg 2 times / day multiple, oral
dose: 1250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
35.3 mg × h/L
1250 mg 2 times / day steady-state, oral
dose: 1250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
43.6 mg × h/L
750 mg 3 times / day multiple, oral
dose: 750 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
52.8 mg × h/L
1250 mg 2 times / day multiple, oral
dose: 1250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.8 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
3.4 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NELFINAVIR MESYLATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
unknown, unknown
NELFINAVIR MESYLATE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Disc. AE: Hyponatremia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Hyponatremia (grade 4, 1 patient)
Thrombocytopenia (grade 3, 1 patient)
Dizziness (grade 3, 1 patient)
Elevated liver enzymes (grade 3, 2 patients)
Sources:
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Disc. AE: Esophagitis, Nausea...
Other AEs: Leukopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Esophagitis (grade 3, 1 patient)
Nausea (grade 3, 1 patient)
Fatigue (grade 3, 1 patient)
Other AEs:
Leukopenia (grade 3, 2 patients)
Thrombocytopenia (grade 3, 2 patients)
Dyspnea (grade 3, 1 patient)
Sources:
650 mg 2 times / day steady, oral
Dose: 650 mg, 2 times / day
Route: oral
Route: steady
Dose: 650 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 5
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 5
Sources:
Other AEs: Thrombocytopenia...
Other AEs:
Thrombocytopenia (grade 4, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Thrombocytopenia grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Elevated liver enzymes grade 3, 2 patients
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Hyponatremia grade 4, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 52 years (range: 25-77 years)
n = 15
Health Status: unhealthy
Condition: Adenoid Cystic Carcinoma
Age Group: 52 years (range: 25-77 years)
Sex: M+F
Population Size: 15
Sources:
Dyspnea grade 3, 1 patient
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Esophagitis grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Fatigue grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Nausea grade 3, 1 patient
Disc. AE
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Leukopenia grade 3, 2 patients
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Thrombocytopenia grade 3, 2 patients
1250 mg 2 times / day steady, oral
MTD
Dose: 1250 mg, 2 times / day
Route: oral
Route: steady
Dose: 1250 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 8
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 8
Sources:
Thrombocytopenia grade 4, 1 patient
650 mg 2 times / day steady, oral
Dose: 650 mg, 2 times / day
Route: oral
Route: steady
Dose: 650 mg, 2 times / day
Sources:
unhealthy, 59 years (range: 54–75 years)
n = 5
Health Status: unhealthy
Condition: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer
Age Group: 59 years (range: 54–75 years)
Sex: M+F
Population Size: 5
Sources:
PubMed

PubMed

TitleDatePubMed
International Congress on Chemotherapy.
1995 Sep
Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors.
1999 Aug 20
Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases.
1999 Dec
Small molecule inhibitor of HIV-1 nuclear import suppresses HIV-1 replication in human lymphoid tissue ex vivo: a potential addition to current anti-HIV drug repertoire.
2000 Aug
Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
2000 Dec
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.
2000 May
In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.
2000 Sep
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
2001
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
2001 Apr
Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome.
2001 Apr 1
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
2001 Apr 13
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.
2001 Apr 13
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.
2001 Apr 15
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.
2001 Aug
Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
2001 Aug 1
Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.
2001 Aug 15
Antiretroviral therapy for previously treated patients.
2001 Aug 9
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
2001 Aug 9
Pharmacology and clinical experience with saquinavir.
2001 Feb
Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study.
2001 Feb
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.
2001 Feb
Genetic analysis of hiv type 1 strains in bujumbura (burundi): predominance of subtype c variant.
2001 Feb 10
Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
2001 Feb 10
An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy.
2001 Feb 16
Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.
2001 Jan 1
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
2001 Jan 20
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
2001 Jan 26
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.
2001 Jan 26
Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.
2001 Jul
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.
2001 Jul 15
Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir.
2001 Jul 6
The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
2001 Jun
Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
2001 Jun
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART.
2001 Jun
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
2001 Jun 1
Design and synthesis of a conformationally restricted trans peptide isostere based on the bioactive conformations of saquinavir and nelfinavir.
2001 Jun 1
Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
2001 Jun 1
Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir.
2001 Mar
Phase III trials for new PI.
2001 Mar
Lack of removal of nelfinavir during a haemodialysis session in an HIV-1 infected patient with hepatic and renal insufficiency.
2001 Mar
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
2001 Mar 1
Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.
2001 Mar 26
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
2001 Mar 30
Nelfinavir desensitization.
2001 May
Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.
2001 May
Patents

Sample Use Guides

The recommended dose is 1250 mg (five 250 mg tablets or two 625 mg tablets) twice daily or 750 mg (three 250 mg tablets) three times daily. VIRACEPT should be taken with a meal. Patients unable to swallow the 250 or 625 mg tablets may dissolve the tablets in a small amount of water. Once dissolved, patients should mix the cloudy liquid well, and consume it immediately.
Route of Administration: Oral
Nelfinavir inhibited intracellular proteasome activity in situ at drug concentrations <40 uM in human primary myeloma cells.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:22:40 UTC 2023
Edited
by admin
on Wed Jul 05 23:22:40 UTC 2023
Record UNII
98D603VP8V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NELFINAVIR MESYLATE
HSDB   ORANGE BOOK   USAN   USP-RS   VANDF  
USAN  
Official Name English
AG1343
Code English
NELFINAVIR MESYLATE [VANDF]
Common Name English
NELFINAVIR MESILATE [JAN]
Common Name English
(3S,4aS,8aS)-N-tert-Butyl-2-[(2R,3R)-3-(3,2-cresotamido)-2-hydroxy-4-(phenylthio)butyl]decahydro-3-isoquinolinecarboxamide monomethanesulfonate (salt)
Common Name English
VIRACEPT
Brand Name English
AG-1343
Code English
NELFINAVIRI MESILAS [WHO-IP LATIN]
Common Name English
NELFINAVIR MESYLATE [ORANGE BOOK]
Common Name English
NELFINAVIR MESYLATE [USAN]
Common Name English
NELFINAVIR METHANESULFONATE [MI]
Common Name English
NELFINAVIR METHANESULFONATE
MI  
Common Name English
NELFINAVIR MESYLATE [HSDB]
Common Name English
Nelfinavir mesilate [WHO-DD]
Common Name English
NELFINAVIR MESILATE [MART.]
Common Name English
NELFINAVIR MESILATE [WHO-IP]
Common Name English
NELFINAVIR MESILATE
JAN   MART.   WHO-DD   WHO-IP  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C97366
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
EMA ASSESSMENT REPORTS VIRACEPT (WITHDRAWN: HIV INFECTIONS)
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
Code System Code Type Description
CAS
159989-65-8
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
RXCUI
266565
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY RxNorm
CHEBI
7497
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
EPA CompTox
DTXSID2033736
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
NCI_THESAURUS
C1624
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
EVMPD
SUB12538MIG
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
DRUG BANK
DBSALT000885
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
NELFINAVIR MESYLATE
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water and soluble in methanol R. Category: Antiretroviral (Protease Inhibitor). Storage: Nelfinavir mesilate should be kept in a tightly closed container, protected from light. Additional information: Nelfinavir mesilate is hygroscopic. Definition: Nelfinavir mesilate contains not less than 98.5% and not more than 101.0% of C32H45N3O4S,CH4O3S, calculated with reference to the dried substance.
PUBCHEM
64142
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
SMS_ID
100000090011
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
ChEMBL
CHEMBL584
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
FDA UNII
98D603VP8V
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
DAILYMED
98D603VP8V
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
HSDB
7159
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
USAN
HH-40
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY
MERCK INDEX
M7798
Created by admin on Wed Jul 05 23:22:40 UTC 2023 , Edited by admin on Wed Jul 05 23:22:40 UTC 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY